Join to View Full Profile
1275 York AveNew York, NY 10065
Phone+1 212-639-5387
Fax+1 212-717-3263
Dr. Bodei is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of GroningenPhD, 2007 - 2009- University of PisaResidency in Nuclear Medicine, Cum Laude, 1995 - 1999
University of Pisa Faculty of MedicineClass of 1995
Certifications & Licensure
NJ State Medical License 2021 - 2027
NY State Medical License 2016 - 2027
CT State Medical License 2024 - 2026
American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver Start of enrollment: 2020 Sep 02
- A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer Start of enrollment: 2021 Sep 14
Roles: Contact
- Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors Start of enrollment: 2024 Jun 03
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers.Salomon Tendler, Roberto De Gregorio, Paul Balderes, Alexa L Michel, Tran T Hoang
Proceedings of the National Academy of Sciences of the United States of America. 2026-02-10 - Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.Aurelie Choucair, Anna Zdunek, Matthew Liao, Lisa Bodei, Desiree Deandreis
Insights Into Imaging. 2026-02-09 - Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, Zeynep C Tarcan, Courtney Porfido
JCO Precision Oncology. 2025-11-01
Journal Articles
- Biodistribution and Radiation Dose Estimates for 68Ga-DOTA-JR11 in Patients with Metastatic Neuroendocrine TumorsSimone Krebs, Lisa Bodei, Diane Reidy, Bradley J Beattie, Wolfgang A Weber, European Journal of Nuclear Medicine and Molecular Imaging
- Blood mRNA Measurement (NETest) for Neuroendocrine Tumors Diagnosis of Image-Negative Liver Metastatic DiseaseIrvin M Modlin, Lisa Bodei, The Journal of Clinical Endocrinology and Metabolism
Lectures
- PRRT neuroendocrine tumor response assessment using blood transcript analysis: The NETest.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Observations from a Biomarker Perspective at ASCO GIFebruary 2020
- Observations from a Biomarker Perspective at ASCO GIFebruary 2020
Press Mentions
How ‘Theranostic’ Drugs Diagnose and Treat at the Same TimeOctober 8th, 2025- Blood Biomarkers Predict Neuroendocrine Tumor Response to Radiopharmaceutical TherapyApril 7th, 2023
- ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate CancerJune 3rd, 2021
Grant Support
- Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostateSLOAN-KETTERING INST CAN RESEARCH2024–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
